Ann Marie O'Neill/aum.edu
May 20, 2026, 08:03
Ann Marie O’Neill: Help Us Improve Information for DOAC Medicines
Ann Marie O’Neill, Operations Manager at The Meath Foundation , Thrombosis Patient Advocate, shared a post on LinkedIn:
“We are inviting people who take Direct Oral Anticoagulant Medication (DOAC) eg. Apixaban (Eliquis) Rivaroxaban (Xaralto) or Dabigatran (Pradaxa) after experiencing a blood clot, to join a small focus group to help us improve our Patient information booklet.
If you are a VTE Health Care Professional, please share with your relevant Patients.
The more the merrier.”
Stay updated with Hemostasis Today.
-
May 20, 2026, 08:03Tareq Abadl: Exploring the Clinical Power of Serum Protein Electrophoresis
-
May 20, 2026, 07:51Haroun Gajraj: Upto 30% of Patients Develop Brown Marks After Microsclerotherapy
-
May 20, 2026, 07:50Karen Schreiber: The BBQ Trial and the Challenge of Conducting Pregnancy RCTs
-
May 20, 2026, 07:49Dilini Christina Ranasinghe: Paediatric TPE Is Not Simply Adult TPE in a Smaller Patient
-
May 20, 2026, 07:42Manuel Carbonell: Combining Sclerotherapy and Laser Technology in Modern Vein Treatment
-
May 20, 2026, 07:15Is Postpartum DOAC Use A Real-World Alternative to LMWH and VKA? – JTH
-
May 20, 2026, 07:07Arman Qamar: Can Ischemic Stroke Polygenic Risk Scores Predict Recurrent Events After Coronary Revascularization?
-
May 20, 2026, 06:59Erin VanDyke: PE Is an Opportunity to Reflect on How We Could Have Better Handled a DVT
-
May 20, 2026, 06:53Fayad Al-Haimus: The TOWAR Trial On Comaprison of Whole Blood vs Component Therapy in Trauma